Articles

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between September 20, 2021, and October 29, 2021. Read More ›

Early results from the CheckMate-648 clinical trial, which evaluated the efficacy and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, suggest a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). Read More ›

The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer and BRCA1 or BRCA2 mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

Read More ›

Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial, presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

Perioperative SOX treatment significantly improved 3-year disease-free survival in patients with locally advanced gastric cancer compared with adjuvant CapOx. Read More ›

Results from a phase 2 clinical trial of the use of zanidatamab with standard first-line chemotherapy in patients with HER2-positive GEA show promising disease control rate and duration of response. Read More ›

Results from a second-line trastuzumab deruxtecan phase 2 study in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer reveal promising response and safety. Read More ›

Comprehensive analysis of immune checkpoints in gastric adenocarcinoma finds ICOSLG and CD70 may serve as prognostic biomarkers for gastric cancer. Read More ›